ABSTRACT
INTRODUCTION
Non-small cell lung cancer (NSCLC) is characterized by a high incidence of brain metastasis. Approximately, 40% of patients diagnosed with NSCLC will develop brain metastasis (BM) during the course of their disease and this risk may be even higher in those with adenocarcinoma with epidermal growth factor receptor (EGFR) mutation [1, 2] . Traditionally, whole brain radiotherapy (WBRT) has been the standard treatment for patients with brain metastases, and stereotactic radiosurgery (SRS) or surgical resection can be used in some cases with limited number of metastasis [3] . Local brain radiotherapy (RT) showed a higher response in terms of local control, but survival remains poor with a median overall survival (OS) ranging from 3 to 15 months [4] . The Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) for patients with NSCLC and brain metastases using molecular markers (Lung-molGPA) has been found to be a user-friendly tool that may facilitate clinical decision making and appropriate stratification [5] .
EGFR tyrosine kinase inhibitors (TKIs) have been recommended as first-line treatment for metastatic NSCLC patients harboring EGFR sensitive mutations. Some studies have shown that EGFR-TKI plus WBRT demonstrated an improved therapeutic effect and median OS after brain metastases of 19.4 to 58.4 months [6, 7] . However, WBRT might lead to long-term impairment of neurocognitive functions and deteriorate patient's quality of life, especially in the EGFR-mutated patients with prolonged survival [8] . EGFR-TKIs have been found to have low to moderate cerebrospinal fluid (CSF) penetration rates within the brain and can achieve therapeutic CSF concentrations, which accounts in part for intracranial responses [9] . Several prospective studies have demonstrated that EGFR-TKIs alone show therapeutic benefits against BM for EGFR-mutant patients, with a response rate of up to 80% [10, 11] . Thus, some hypothesize that NSCLC patients with EGFR mutation and brain metastases could receive EGFR-TKI alone first, and brain RT may be delayed until tumor progression on brain imaging or symptomatic progression, thereby delaying radiation-related neurotoxicitis [12, 13] . The recently published multi-institutional analysis demonstrated that the use of upfront EGFR-TKI with deferral of radiotherapy is associated with inferior OS in patients with EGFR-mutant NSCLC who develop brain metastases [14] . Meanwhile, other studies showed that addition of brain RT to EGFR-TKIs did not appear to have survival benefit compared to that of EGFR-TKI treatment alone in EGFR-mutant NSCLC with BM [15, 16] . Therefore, the management of EGFR mutated NSCLC patients with brain metastases is a significant clinical challenge and remains controversial.
In this study, we selected NSCLC patients with brain metastases who had good responses to EGFR-TKI to examine the role of early brain RT on intracranial disease control and survival.
RESULTS

Patient characteristics
Among a total 520 consecutive NSCLC patients treated with EGFR-TKI in our Institution, 113 patients met the inclusion criteria. Of these 113 patients, 49 (43%) received brain RT within 4 weeks after EGFR-TKI initiation and 64 (57%) were treated with EGFR-TKI alone as an initial therapy, including 27 received salvage brain RT at intracranial progression and 37 had EGFR-TKI alone. Table 1 shows the baseline characteristics of the patients. Patients with early brain RT were more likely to be symptomatic from their BMs (80% early RT v. 13% EGFR-TKI alone v. 33% salvage RT, P<0.001). There were more patients with a less favorable prognosis in early RT group (DS-GPA of 0-2.0: 86% early RT v. 51% EGFR-TKI v. 78% deferred RT, P=0.002). No other significant differences between groups were found.
Treatment characteristics
All the patients were treated with EGFR-TKI monotherapy (gefitinib 250mg q.d. or erlotinib 150mg q.d. or icotinib 125mg t.i.d). If the patient had significant symptoms from BMs or the BMs were in a critical location, early WBRT or SRS was administered within 4 weeks after EGFR-TKI initiation. WBRT was delivered with a dose of 30Gy in 10 fractions or 37.5Gy in 15 fractions using 6MV photons with opposed lateral fields. SRS was delivered with a Leksell Gamma Knife model C.
Progression of disease (extracranial or intracranial) was observed in 84.1% of the 113 patients. Treatment for disease progression included chemotherapy (42.1%), continued EGFR-TKI treatment (23.2%), osimertinib (6.3%), clinical trial (2.1%), other therapy (4.2%) and no further systemic therapies (22.1%). There was no significant difference in terms of salvage systemic therapy between EGFR-TKI and early RT group. Among EGFR-TKI alone group, 48 patients had BMs progression, 27 (56.2%) received salvage brain RT. While in early RT group, 10 patients (23.8%) had salvage brain RT.
Pattern of failure
The median follow-up time for all the 113 patients was 30.0 months (range, 6.0-57.0 months) upto the study closing date of March 30, 2016. Ninety-five patients (84.1%) experienced disease progression, including 29 patients (30.5%) with isolated intracranial failure, 34 patients (35.8%) with both intracranial and extracranial failure and 32 patients (33.7%) with isolated extracranial failure. In patients with early RT, 24 (57.1%) had BM progression including 10 (23.8%) patients with isolated intracranial failure and 14 (33.3%) patients with both intracranial and extracranial failure. While, in patients without early RT, 39 (73.6%) patients had BM progression including 19 (35.8%) patients with isolated intracranial failure and 20 (37.7%) patients with both intracranial and extracranial failure. Patterns of intracranial and extracranial failure are shown in Table 2 . Of the 95 patients with disease progression, 73.6% of patients (39/53) without early RT experienced intracranial failure www.impactjournals.com/oncotarget 
Intracranial progression
Of all the 113 patients, before salvage brain RT, the median intracranial progression free survival (IC-PFS) was 17.7 months (95% CI 14.4-21.0 months). The median IC-PFS of patients with early RT was significant longer than those without early RT (21.4 vs 15.0 months, P=0.001, Figure 1 ). The effect of early brain RT on IC-PFS remained significant on multivariate analysis (HR 0.34; 95% CI 0.19-0.61; P<0.001). However, after salvage brain RT, the IC-PFS did not differ significantly between the salvage RT and early RT groups (23.6 vs 21.4 months, P=0.253, Figure 2 ). No significant difference of the IC-PFS was found between the patients with salvage RT and those with EGFR-TKI alone (23.6 vs 24.4 months, P=0.277). 
Survival outcomes
At the time of analysis, 54 patients were alive. For the entire cohort, the median overall survival (OS) from the first-day treatment with EGFR-TKI was 25.5 months (95% CI, 23.9-27.1). The median OS for early brain RT, EGFR-TKI alone and salvage brain RT groups was 28.1 months (95% CI, 17.9-38.3), 24.5 months (95% CI, 20.6-28.4), and 24.6 months (95% CI, 19.0-30.1), respectively (P=0.604; Figure 3 ). No significant difference in OS was observed between patients with early RT and those with salvage RT (28.1 vs 24.6 months, P=0.385).
Additional subgroup analyses
Considering the significant difference in symptoms of BM and DS-GPA scores between the groups at baseline, we focused on the role of early brain RT in 71 patients with DS-GPA scores of 0 to 2 who had a definite EGFR mutation. For these patients, the median OS was 24.5 months (95% CI .040) was an independent factor for poorer OS and early brain RT (HR 0.33; 95% CI 0.12-0.87; P=0.025) was an independent factor for improved OS (Table 3) . Such findings were not observed in patients with higher GPA scores.
DISCUSSION
The optimal treatment combination or sequence of patients with EGFR mutation and BM has been unclear. We hereby present this retrospective study to investigate the use of brain RT with EGFR-TKI given at initial presentation or disease progression in NSCLC patients with EGFR mutation and BMs. Although not all the patients in our study had known status of EGFR mutations, their tumors were all controlled by EGFR-TKI for more than 6 months. Therefore the likelihood that the patients harbored sensitive EGFR mutation was high.
This study demonstrated that patients treated with EGFR-TKI and early brain RT achieved a significantly longer IC-PFS than those initially treated with EGFR-TKI alone on both univariate and multivariate analyses, with a median IC-PFS of 21.0 months and 15.0 months, respectively (P=0.001). This is consistent with the literatures that reported by Naamit K and William J [6, 7] , but patients in these two studies were not treated concurrently with brain RT and EGFR-TKI. Preclinical data showed that cells with EGFR mutations are radiosensitive and EGFR-TKI is considered to be a radiosensitizer [17, 18] . A single arm phase 2 trial of erlotinib plus concurrent WBRT conducted in an unselected population reported that the combination of erlotinib and WBRT was both safe and effective [19] . Zeng et al reported that gefitinib plus concomitant WBRT was associated with higher BM response rate and significant improvement in OS compared with gefitinib alone in treatment of BM from unselected NSCLC [20] . It is reasonable to hypothesize that the combination of EGFR-TKI and brain RT for EGFR-mutant NSCLC would result in significantly improved intracranial disease control. Our study reconfirms previous findings of improved intracranial disease control in EGFR-mutant patients receiving brain RT plus EGFR-TKI compared with those receiving TKI alone. The attribution of the enhanced effectiveness might be synergistic effects of EGFR-TKI and brain RT. Further prospective study is needed to validate this finding.
Some limited studies recommended patients harboring EGFR mutation with brain metastases to receive EGFR-TKI first, in the hopes of delaying or obviating the need of WBRT and the subsequent risks of neurocognitive side effects from brain RT [13, 21] . There is an ongoing trial of comparing upfront erlotinib with WBRT at initial presentation to erlotinib alone with WBRT at disease progression in patients with EGFRmutant lung adenocarcinoma with BM (clinicaltrials. gov ID NCT01763385), with mature data pending. We found that after salvage brain RT, IC-PFS and OS of the patients did not differ significantly between early RT and salvage RT group, with a median IC-PFS of 23.6 months and 21.4 months, respectively (P=0.253) and a median OS of 24.6 months and 28.1 months, respectively (P=0.383). These results suggest that the use of early TKI, with deferral of RT until intracranial progression was not associated with inferior IC-PFS and OS. Additionally, for those asymptomatic from BM or did not experience CNS progression with effective systemic therapy, patients may be spared from concerns of neurotoxicitis from early brain RT.
Our study showed that there was no significant difference of OS between the early RT, EGFR-TKI alone and salvage RT groups (28.1 months vs. 24.5 months vs. 24.6 months, P=0.604). It seemed that the addition of brain RT to EGFR-TKIs did not appear to have survival benefit to that of EGFR-TKI alone in EGFR-mutant NSCLC with BM. However, one has to note that the patients with early RT had more poor prognostic factors than those without early RT. The similar OS between these groups may suggest effectiveness of brain RT. It is possible that omission of brain RT in these patients with poor prognostic factors might result in worse survival. This data is hypothesis generating. A prospective randomized study is needed to answer this question.
It would be desirable to identify those patients at high risk for brain relapse for early brain RT in combination of EGFR-TKI to improve survival. However, there are no reliable predictive factors. DS-GPA is a user-friendly prognostic index for patients with brain metastases. Subgroup analysis of our study showed that in patients with DS-GPA scores of 0 to 2, early brain RT was an independent factor for improved OS (HR 0.33; 95% CI 0.1-0.9; P=0.025), but this was not observed in patients with higher GPA scores. Therefore, low DS-GPA scores may help to select patients for upfront brain RT to improve survival.
Our study has several limitations that should be acknowledged. First, these data represent the single institution experience and the number of patients included in the analysis was relatively small. Second, this is a retrospective study and carries all of the biases inherent in such an analysis. Although all the patients in the study had good response to EGFR-TKI treatment, some patients had unknown EGFR mutations, which might have induced selection bias. There may also have been study bias with respect to patients requiring early RT and salvage RT. Third, we combined SRS and WBRT patients may mask some differences regarding the effect of RT or appropriateness of RT in these patients. Fourth, treatment groups were not homogenous regarding to baseline characteristics, dose of radiation, EGFR-TKI drugs and subsequent systemic therapies. Finally, we did not account for the potential toxicities related with brain therapies and their impact on quality of life.
In summary, our study suggested that concurrent early brain RT with EGFR-TKI may improve intracranial disease control compared with TKI alone in EGFR-mutant NSCLC with BM. The addition of brain RT to EGFR-TKI as initial therapy did not appear to improve survival in unselected patients, but in patients with low DS-GPA scores 0-2. Further prospective studies are needed to validate these findings and determine the optimal timing and appropriate patient group who need early brain RT.
MATERIALS AND METHODS
Study design and patients
Between January 2008 and October 2015, NSCLC patients treated with EGFR-TKI were reviewed at our institution. We included patients with known BM before EGFR-TKI treatment and excluded patients who developed BM after starting EGFR-TKI. Tumor response was determined by Evaluation Criteria in Solid Tumor (RECIST) version 1.1. "Good response" to EGFR-TKI was defined as complete response (CR), partial response (PR) and stable disease (SD). Patients who developed brain metastases after first line chemotherapy were also included. The patients treated with surgical resection at the time of initial brain metastases were excluded in order to remove potentially confounding variables. The treatment response was evaluated 1 month after the initiation of EGFR-TKI therapy and then every 2 months. All patients received an initial gadolinium-enhanced brain MRI prior to EGFR-TKI start and every 8-12 weeks after EGFR-TKI treatment. A DS-GPA was calculated for each patient. The study was reviewed and approved by the Review Board of West China Hospital of Sichuan University.
Statistical analyses
IC-PFS was defined as survival from TKI initiation to intracranial progression after brain RT if any. OS was calculated from the date of the administration of TKI until the date of death from any cause. Patients alive at the date of statistical analysis were censored at the last follow-up. The Pearson chi-square test or the Fisher exact test was used to compare patients' characteristics and site of first failure between the different treatment groups. The Kaplan-Meier method was used to perform survival analysis, and survival curves were compared using the log-rank test. A Cox proportional hazards model was used for univariate and multivariate survival analyses to calculate the hazard ratios (HRs) and corresponding 95% confidence intervals (CIs). Two-sided values of P<0.05 were considered statistically significant. All statistical analyses were performed with SPSS 22.0.
